Chronic Fatigue Therapy Tablet, Orally Disintegrating
NDC Package 17312-170-14
Package Information
Chronic Fatigue Therapy (epinephrine, gold, chelidonium majus, echinacea, ginkgo, helleborus niger, phosphoric acid, scutellaria lateriflora, thuja occidentalis) tablets is suitable for adults and children ages 2 and over. This formulation utilizes a tablet, orally disintegrating delivery system. Marketed by Trp Company, this product is identified by NDC 17312-170.
Identification & Billing
Clinical Specifications
- Adrenergic alpha-Agonists - [MoA] (Mechanism of Action)
- Adrenergic beta-Agonists - [MoA] (Mechanism of Action)
- Allergens - [CS]
- Catecholamine - [EPC] (Established Pharmacologic Class)
- Catecholamines - [CS]
- Cell-mediated Immunity - [PE] (Physiologic Effect)
- Increased Histamine Release - [PE] (Physiologic Effect)
- Standardized Chemical Allergen - [EPC] (Established Pharmacologic Class)
- alpha-Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
- beta-Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 17312 - Trp Company
- 17312-170 - Chronic Fatigue Therapy
- 17312-170-14 - 1 BOTTLE in 1 PACKAGE / 70 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE
- 17312-170 - Chronic Fatigue Therapy
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 17312-170-14 identifies a specific commercial package of 1 bottle in 1 package / 70 tablet, orally disintegrating in 1 bottle of Chronic Fatigue Therapy, a human over the counter drug labeled by Trp Company. This tablet, orally disintegrating is formulated for oral use and contains chelidonium majus; echinacea, unspecified; epinephrine; ginkgo; gold; helleborus niger root; phosphoric acid; scutellaria lateriflora; thuja occidentalis leafy twig as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Trp Company on August 20, 2018. The current certification is valid through December 31, 2026.
How is this Trp Company product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 17312017014. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.